Replies to post #191729 on Biotech Values

[jbog]

It's probably a model we should have seen for a long time and I'm guessing it's something we'll see going forward.

Talking about Gilead, I'm starting to wonder if we're seeing the peak in HCV treatment from Gilead. The recent script data has leveled off.